Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $3.30, but opened at $3.39. Evotec shares last traded at $3.40, with a volume of 17,661 shares trading hands.
Evotec Stock Performance
The business's 50-day moving average is $3.69 and its two-hundred day moving average is $4.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Investors Weigh In On Evotec
Large investors have recently bought and sold shares of the company. DCF Advisers LLC grew its holdings in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after buying an additional 12,816 shares during the period. BNP Paribas Financial Markets acquired a new position in Evotec in the fourth quarter valued at about $27,000. Bank of America Corp DE increased its holdings in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec during the fourth quarter worth about $166,000. Finally, CSS LLC IL bought a new position in shares of Evotec during the 4th quarter valued at about $50,000. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
